Search criteria | ||||
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis | ||||
Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó | ||||
"a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany" | ||||
, Article | ||||
, Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
Abstract: https://www.tandfonline.com/doi/full/10.1080/03007995.2023.2256220 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders | 2023 | English | , clinical setting: Secondary care, Epidemiological study, Population Based Study | |
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets | ||||
Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group | ||||
1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. 2The Alfred Hospital, Melbourne, Australia. 3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France. 4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA). 5Global Database Studies, IQVIA, Tartu, Estonia. 6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands. 7IQVIA (former EPID Research), Espoo, Finland. 8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. | ||||
Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977 |
||||
, Article | ||||
, Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/35357268/ | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Neurological disorders | 2022 | English | , clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis | |
Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus and Influenza Related Hospitalizations in Adults – A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study) | ||||
Ann R Falsey, Edward E Walsh, Stacey House, Yannick Vandenijck, Xiaohui Ren, Sofia Keim, Diye Kang, Pascale Peeters, James Witek, Gabriela Ispas | ||||
University Of Rochester School Of Medicine and Rochester Regional Health, Rochester, NY, United States; Washington University School of Medicine, St Louis, MO, United States; Janssen Infectious Diseases, Beerse, Belgium; IQVIA Real-World Solutions, Courbevoie, France; Janssen Research & Development, LLC, Titusville, NJ, United States | ||||
, Article | ||||
, Argentina, Australia, Brazil, Canada, France, Germany, Japan, Korea, Malaysia, Mexico, South Africa, USA | ||||
Abstract: https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab491/6381446 | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease | 2021 | English | , Burden of illness, Clinical setting: hospital, Epidemiological study, Observational study, Patient questionnaire, Prospective study | |
Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer | ||||
Gomez-Ulloa D1, Amonkar M2, Kothari S3, Cheung WY4, Chau I5, Zalcberg J6, Lara N1, Falcone A7 | ||||
1 IQVIA, Barcelona, Spain 2 Merck & Co., Inc., North Wales, PA, US 3 Merck & Co., Inc., Kenilworth, NJ, US 4 British Columbia Cancer Agency, Vancouver, BC, Canada 5 Royal Marsden Hospital, London, UK 6 Alfred Health, Melbourne, Australia 7 University of Pisa, Pisa, Italy | ||||
BMC Gastroenterology BMC Gastroenterology volume 20, Article number: 133 (2020) |
||||
, Article | ||||
, Australia, Canada, Italy, UK | ||||
Abstract: https://doi.org/10.1186/s12876-020-01232-z | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2020 | English | , Retrospective cohort analysis | |
Investigation of factors considered in the health technology assessment conducted by regulatory authority in eight countries | ||||
Akira Yuasa 1, Naohiro Yonemoto 1, Sven Demiya 2, Chihiro Foellscher 2, Shunya Ikeda 3 (rwesheorj 2) | ||||
1) Pfizer Japan Inc., Tokyo, Japan 2) IQVIA Solutions Japan, Tokyo, Japan 3) Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan | ||||
ISPOR 2020 Conference |
||||
, Abstract | ||||
, Australia, Canada, France, Germany, Italy, Japan, Spain, UK | ||||
Abstract: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/101019 | ||||
Condition | Year | Language | Analysis type | |
2020 | English | |||
Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients | ||||
Skelly A1, Bezlyak V1, Liew G2, Kap E3, Sagkriotis A1 | ||||
1. Novartis Pharma AG, 4002 Basel, Switzerland; 2. Westmead Institute for Medical Research, University of Sydney, Westmead NSW 2145, Australia; 3. IQVIA Commercial GmbH & Co. OHG, 60549 Frankfurt, Germany | ||||
, Article | ||||
, Australia | ||||
Abstract: https://doi.org/10.3390/vision3030041 | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2019 | English | , clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis | |
Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC) | ||||
Amonkar M1, Gomez-Ulloa D2, Smita Kothari1, Cheung WY3, Chau I4, Zalcberg JR5, Lara N2, Falcone A6 | ||||
1 Merck & Co., Inc., Kenilworth, NJ, USA 2 IQVIA, Barcelona, Spain 3 British Columbia Cancer Agency, Vancouver, BC, Canada 4 Royal Marsden Hospital, London, UK 5 Alfred Health, Melbourne, Australia 6 University of Pisa, Pisa, Italy | ||||
BMC Gastroenterology volume 20, Article number: 133 (2020) |
||||
, Poster | ||||
, Australia, Canada, Italy, UK | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2019 | English | , Retrospective cohort analysis | |
Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD) | ||||
Mitrofan L1 , M.R. Krukas-Hampel M.R2 , L.A. Mendoza L.A3 | ||||
IQVIA, Paris, FR; IQVIA New York, US; IQVIA, Prague, CZ | ||||
ESMO 2018 |
||||
, Poster | ||||
, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data | ||||
Mitrofan L.M.1,Krukas-Hampel M.R.2, Mendoza L.A.3 | ||||
1 IQVIA, Paris, FR; 2IQVIA New York, US; 3IQVIA, Prague, CZ | ||||
ESMO 2018 |
||||
, Poster | ||||
, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Spain, Taiwan, UK | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
Identifying the confuonders that explain the difference in readouts between non-interventional and randomized controlled trials: the case of treatments in neovascular age-related macular degeneration | ||||
Sakriotis A1, Griner R2, Durus A1, Doyle OM2, Rodriguez-Torres L1, Wintermantel T2, Clemens A13 | ||||
1. Novartis Pharma AG, Basel, Switzerland; 2. IQVIA Real World Insights, Switzerland/UK/US; 3. Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany | ||||
ISPOR Europe, Barcelona, Spain, 10-14 November 2018 |
||||
, Poster | ||||
, Australia, UK, USA | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2018 | English | , clinical setting: Secondary care, Epidemiological study, Observational study, Retrospective database analysis | |
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom. | ||||
Johnston RL1,2, Carius HJ3, Skelly A4, Ferreira A5, Milnes F4, Mitchell P6. | ||||
1 The Royal College of Ophthalmologists' National Ophthalmology Database, London, UK. 2 Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. 3 QuintilesIMS, Frankfurt am Main, Germany. 4 Novartis Pharma AG, Basel, Switzerland. 5 Novartis Pharma AG, Basel, Switzerland. alberto.ferreira@novartis.com. 6 Department of Ophthalmology, Westmead Millennium Institute, University of Sydney, Westmead, NSW, Australia. | ||||
Advances in therapy |
||||
, Article | ||||
, Australia, UK | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28144918 | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2017 | English | , Retrospective cohort analysis | |
Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model | ||||
Gerlier L1, Hackett J2, Lawson R2, Dos Santos Mendes S3, Weil-Olivier C4, Schwehm M5, Eichner M6,7 | ||||
1 QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium 2 AstraZeneca, Gaithersburg, MD, USA 3 AstraZeneca, Brussels, Belgium (Current affiliation: MSD, Brussels, Belgium) 4 Department of Pediatrics, University Paris VII, Paris, France 5 ExploSYS GmbH, Leinfelden-Echterdingen, Germany 6 Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany 7 Epimos GmbH, Dusslingen, Germany | ||||
JHEOR 2017;5(1):89-108 |
||||
, Article | ||||
, Australia, Belgium, Finland, France, Germany, Greece, Italy, Luxembourg, Netherlands, Poland, Portugal, Spain, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, Immunology and Vaccination, Infectious disease, Respiratory disease | 2017 | English | , Epidemiological study, Public Health | |
HEALTH-ECONOMICS EVALUATIONS IN FRANCE, ENGLAND, CANADA AND AUTRALIA: COMPARISON OF METHODOLOGIES AND IMPACT ON DRUGS | ||||
Bucher D*, Abalan M-E*, Allou A*, Dumon L*, Vialard L *, Troubat A*, Maurel F* | ||||
IQVIA France - RWI | ||||
ISPOR 2017 |
||||
, Poster | ||||
, Australia, Canada, France, UK | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2017 | English | , Cost effectiveness, Literature Review, Pricing & Reimbursement, Review | |
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. | ||||
Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. | ||||
1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden. | ||||
Clinical Epidemiology |
||||
, Article | ||||
, Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK | ||||
Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/ | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2016 | English | , Literature Review | |
Drug Utilization Study for Lisdexamfetamine Dimesylate (LDX) in Australia | ||||
von Bredow D1, Ehlken B1, Blumentals WA2, Kolb N1, Keja J1, Maxwell T2 | ||||
1 IMS HealthGmbH & Co. OHG, Munich, Germany, 1 Shire Pharmaceuticals, Lexington, MA, USA | ||||
32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) |
||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2016 | English | , Database Study, Survey research | |
Medical resource use and associated costs in open-angle glaucoma in 10 Asia-pacific countries. | ||||
Gerlier L1, Lamotte M1, Caputo J2, Tan R3 | ||||
1 IMS Health Consulting EMEA, Vilvoorde, Belgium 2 IMS Health Consulting Asia-Pacific, Singapore 3 ALCON, Asia-Pacific, Singapore | ||||
5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
||||
, Abstract, Poster | ||||
, Australia, China, Hong Kong, India, Malaysia, New Zealand, Singapore, South Korea, Taiwan, Thailand | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2012 | English | , Burden of illness | |
Health economics review of bowel cancer in Australia | ||||
Bishop J, Glass P, Tracey E, Hardy M, Warner K, Makino K, Gordois A, Wilson J, Guarnieri C, Feng J, Sartori L | ||||
NSW Cancer Institute, Sydney |
||||
, Review | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | English | , Cost effectiveness | |
Remote monitoring systems for patients with implanted cardiac devices | ||||
Medical Services Advisory Committee (MSAC), Australian Government Department of Health and Ageing. | ||||
Department of Health and Ageing, Canberra: Australia |
||||
, Report | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2008 | English | , Review | |
Endobronchial ultrasound-guided procedures | ||||
Medical Services Advisory Committee (assessors, Pricing and Market Access, Sydney) | ||||
Published by the Commonwealth of Australia |
||||
, Review | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice | 2008 | English | , Review | |
Cost-effectiveness analysis of smoking cessation pharmacotherapies in Australia | ||||
Bhatti T, Makino K, Guarnieri C, Gordois A, Cotter T, Perez D, Bishop J, Glass P | ||||
ISPOR 3rd Asia-Pacific Conference, Seoul, Korea, September 2008 |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | English | , Cost effectiveness | |
Pharmacotherapy evaluation: Drugs that assist smoking cessation | ||||
Perez D, Cotter T, Makino K, Bhatti T, Gordois A, Guarnieri C, Lewis S, Glass P, Bishop J | ||||
Sydney: Cancer Institute NSW |
||||
, Report | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | English | , Economic evaluation | |
Hepatitis B virus DNA testing | ||||
Medical Services Advisory Committee (assessors Pricing and Market Access, Sydney Australia) | ||||
Commonwealth of Australia |
||||
, Review | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease | 2008 | English | , Review | |
Valuation of schizophrenia-related health states by the general population using the AQoL, time trade-off and visual analogue scales | ||||
Adams J, LeReun C, Crowley S, Nand V, Eggleston A, Schrover R | ||||
ISPOR 10th Annual Meeting |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2008 | English | , Burden of illness | |
Deriving utility values from the general population for induction chemotherapy administered before concurrent chemotherapy-radiation therapy in the treatment of head and neck cancer | ||||
Cordony A, Yuen C, Kovacs G, Guarnieri C, Adams J | ||||
ISPOR 11th Annual European Congress 8–11 November 2008 Athens Greece ISPOR 11th Annual European Congress, Athens Greece, November 2008 |
||||
, Oral presentation, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2008 | English | , Utility analysis | |
Endoscopic ultrasound guided fine-needle aspiration for the staging of non-small cell lung cancer and the diagnosis of mediastinal masses | ||||
Medical Services Advisory Committee (assessors Pricing and Market Access, Sydney Australia) | ||||
Commonwealth of Australia |
||||
, Review | ||||
, Australia | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17296659?dopt=Abstract | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2008 | English | , Review | |
Developing key performance indicators for the Australian reimbursement system | ||||
Abela M, Davey P, Carroll J, Brown B, Yates R | ||||
ISPOR 10th Annual Meeting |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2008 | English | , Pricing & Reimbursement | |
Health Economic Comparison between Continuous Subcutaneous Insulin Infusion (CSII) and Multiple Daily Injections (MDI) of Insulin for the Treatment of Adult and Adolescent Type 1 Diabetes in Australia. | ||||
Cohen N, Minshall ME, Nash L, Zakrzewska, K, Valentine WJ, Palmer AJ. | ||||
In press, PharmacoEconomics, 2008. |
||||
, Manuscript in preparation | ||||
, Australia | ||||
Abstract: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=22007002138 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2007 | English | ||
Australian Schizophrenia Care and Assessment Programme: Real-world schizophrenia: Economics | ||||
Fitzgerald PB, Montgomery W, de Castella AR, Filia KM, Filia SL, Christova L, Jackson D, Kulkarni J | ||||
Australian and New Zealand Journal of Psychiatry 2007 41:10 (819-829) |
||||
, Article | ||||
, Australia | ||||
Abstract: http://www.unboundmedicine.com/medline/ebm/record/17828655/abstract/Australian_Schizophrenia_Care_and_Assessment_Programme:_real_world_schizophrenia:_economics_ | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2007 | English | , Economic evaluation | |
More Policy Initiatives in the Australian National Reimbursement System That Will Reduce Costs Dramatically | ||||
Davey PJ, Abela MJ and Aristides M. | ||||
ISPOR Ninth Annual International Meeting, Arlington, VA. May 16-19, 2004. |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2007 | English | ||
Fetal fibronectin test for predicting pre-term labour | ||||
Medical Services Advisory Committee (assessors pricing and Market Access Sydney Australia) | ||||
Commonwealth of Australia |
||||
, Review | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Womens Health | 2007 | English | , Review | |
The efficacy of insulin glargine compared to other injectable therapies - A meta-analysis of clinical outcomes in insulin naïve type 2 diabetes patients | ||||
Pascoe K, McDonald-Everett CM, FitzGerland P, Yurgin NR, | ||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2006 | English | , Meta analysis | |
The efficacy of insulin glargine compared to other injectable therapies—a meta-analysis of clinical outcomes in insulin naïve type 2 diabetes patients | ||||
Pascoe K, McDonald-Everett CM, FitzGerald P, Yurgin NR, Secnik K | ||||
ISPOR 9th Annual European Congress |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2006 | English | , Meta analysis | |
Carer's perspective ON the valuation OF schizophrenia-related health states USING the assessment OF quality OF life questionnaire AND the EQ5D | ||||
Adams J, Le Reun C, Crowley S, Eggleston A | ||||
, Oral presentation | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | , Quality of life | |
Quantifying the impact of fear of hypoglycaemia on quality of life | ||||
Walters N, Gordois A, Brown A, Lindsay P, Gonzalo F, Comas S | ||||
ISPOR 9th Annual European Congress |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2006 | English | , Burden of illness | |
Recent policy initiatives in the Australian national reimbursement system that have reduced cost dramatically | ||||
Peter Davey. | ||||
ISPOR 11th Annual International Meeting ISPOR 11th International Meeting, 20-24 May 2006 Philadelphia, Pennsylvania, USA. Podium presentation. |
||||
, Oral presentation | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy | 2006 | English | , Pricing & Reimbursement | |
A carer’s perspective on the value of schizophrenia-related health states using the Assessment of Quality of Life Questionnaire and the EUROQoL (EQ5D). | ||||
Adams J, LeReun C, Crowley S, Eggleston A, Schrover R | ||||
ISPOR 9th Annual European Congress |
||||
, Oral presentation | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2006 | English | , Burden of illness | |
Preference and willingness-to-pay for the treatment of schizophrenia from a carer’s perspective | ||||
Adams J, Nand V, Le Reun C, Crowley S, Eggleston A, Schrover R, Brown A | ||||
ISPOR 2nd Asia-Pacific conference |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2006 | English | , Willingness to pay | |
The impact of schizophrenia on caregivers: burden of illness and quality of life. | ||||
Adams J, Nand V, Le reun C, Mudge M, Crowley S, Eggleston A, Schrover R, Brown A, | ||||
ISPOR 2nd Asia-Pacific conference ISPOR 2nd Asia-Pacific Congress,Shanghai, China |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2006 | English | , Burden of illness | |
Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal versus long-term cyclosporin therapy in Australia | ||||
Gordois A, Nobes M, Toohey M, Russ G | ||||
Clinical Transplantation. 20:4, 526–536 |
||||
, Article | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Nephrology | 2006 | English | , Cost effectiveness | |
Assessing the health and economic impact of schizophrenia on carers: a pilot study | ||||
Adams J, Nand V, Le Reun C, Mudge M, Crowley S, Eggleston A, Schrover R, Brown A. | ||||
ISPOR 2nd Asia-Pacific conference, Worldfield Convention Hotel, Shanghai, China |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2006 | English | , Economic evaluation, Quality of life | |
Cost-effectiveness of olanzapine versus lithium for the prevention of relapse in bipolar I disorder in Australia | ||||
Price N, Davey P, Mudge M, FitzGerald P, Rajan N, Montgomery B. | ||||
ISPOR 11th International Meeting, 20-24 May 2006 Philadelphia, Pennsylvania, USA. . ISPOR 2nd Asia-Pacific conference, Worldfield Convention Hotel, Shanghai, China |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2006 | English | , Cost effectiveness | |
Preference and willingness-to-pay for the treatment of schizophrenia from a carer's perspective | ||||
Adams J, Nand V, Le Reun C, Crowley S, Eggleston A, Schrover R, Brown A. | ||||
ISPOR 2nd Asia-Pacific conference, Worldfield Convention Hotel, Shanghai, China |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2006 | English | , Willingness to pay | |
Use patterns and outcomes associated with typical depot antipsychotic agents in the Schizophrenia Care Assessment Program (SCAP) in Australia | ||||
Montgomery B, Christova L, Mudge M, Davey P. | ||||
ISPOR 11th Annual International Meeting ISPOR 11th International Meeting, 20-24 May 2006 Philadelphia, Pennsylvania, USA. Podium presentation. |
||||
, Oral presentation | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2006 | English | , Compliance | |
Valuation of schizophrenia related health states by the general population using the assessment of quality of life questionnaire, time trade-off and visual analogue scales | ||||
Adams J, Le Reun C, Crowley S, Nand V, Eggleston A, Schrover R. | ||||
ISPOR 2nd Asia-Pacific conference ISPOR 2nd Asia-Pacific conference, Worldfield Convention Hotel, Shanghai, China |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Mental health | 2006 | English | , Burden of illness, Quality of life | |
High energy transurethral microwave thermotherapy for benign prostatic hyperplasia. Assessment report. | ||||
Medicare Services Advisory Committee (MSAC). | ||||
Department of Health and Ageing, Commonwealth of Australia. Canberra. |
||||
, Manuscript in preparation | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2006 | English | ||
Establishing effeciveness of a pharmacy based asthma care program | ||||
Saini B, Armour C, Brilliant M, Bosnic-Anticevich S, Krass I, Smith L, Gordois A, Burton D, Emmerton L, Stewart K | ||||
From Cell to Society 5. 5th Biennial Health Research Conference |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2006 | English | , Cost analysis | |
Laparoscopic remotely assisted radical prostatectomy | ||||
Medical Services Advisory Committee (assessors Pricing and Market Access Sydney Australia) | ||||
Commonwealth of Australia |
||||
, Review | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Urology | 2006 | English | , Review | |